n elderly patients, cardiovascular disease is the most common cause of morbidity and mortality. 1 Elderly subjects with coronary artery disease differ from younger patients in many ways; for example, a previous history of myocardial infarction (MI), unstable angina pectoris, multi-vessel disease and complex lesions are more frequent than in a younger population. [2] [3] [4] [5] Several studies have demonstrated that stent implantation for the treatment of coronary lesions is superior to conventional balloon angioplasty during either a short-or longterm follow-up period. [6] [7] [8] [9] [10] Parallel to the developments in procedural techniques and medication, stent deployment for coronary revascularization is being implemented widely in the general population as well as in elderly subjects.
Angiographic evaluations were performed by digital calipers and/or visual estimation by at least 2 experienced cardiologists. Pre and post procedural angiograms were obtained in a minimum of 2 orthogonal views and the lesion characteristics were based on the end-diastolic frame images at which the lesion could be observed at its narrowest. A contrast-media filled guiding catheter was used as the reference for calibration.
Bail-out stenting was defined as the placement of a stent as a consequence of acute complete occlusion or threatening occlusion following PTCA. Acute complete stent occlusion was considered as TIMI Grade 0 flow following PTCA, and a threatening occlusion considered as more than 50% stenosis and evidence of ischemia or dissection. A residual stenosis of more than 20% following PTCA was considered to be sub-optimal. Elective stent placement was performed in re-stenosed lesions and in de novo lesions that were considered eligible for this procedure by at least 2 experienced cardiologists.
Follow-up
Clinical follow up was obtained by examination of the patients by a cardiologist or by telephone interview. In all contacted patients, death, Q wave MI and any revascularization procedure were recorded. Survival and event-free survival were calculated from the date of the procedure to the date of adverse event.
In the elderly patients, 93 subjects (75 men, 18 women) whose long-term (>3 years) clinical follow-up was available, were included in the study. Within the context of the study, patients' consent was obtained, and new coronary angiography was performed on 45 of them. The findings from the last angiography examination of the 15 subjects who had undergone coronary angiography within the previous year and who had had no cardiac complaints or signs of ischemia, were pooled together with the study results. Of the 93 patients, there were 7 who underwent coronary artery bypass grafting (CABG) during the earlier follow-up and who did not have any complaints at present, and for these patients, the results of their last angiography prior to CABG were included in the study.
Definitions
Angiographic Success Residual stenosis less than 20% of the target lesion in the post-procedural angiographic evaluation.
Procedural Success Angiographic success with no major cardiac events during the stenting procedure.
Major Cardiac Event (MCE) Death, new non-fatal MI and any new revascularization procedure. New Q-wave MI was defined as the presence of a new pathologic Q wave in at least 2 concomitant leads in the 12-lead control electrocardiogram (ECG).
Restenosis 50% or more stenosis at the stent site compared with the diameter of the reference vessel of the control coronary angiography image.
Medication
Heparin (15,000 IU) was administered to all patients prior to the procedure and additional boluses were given during the procedure to maintain an activated clotting time ≥300 s. Ticlopidine was started at a dose of 250 mg/day b.i.d. the day before the procedure in some selected patients and on the day of the procedure for the remaining cases, and was continued at the same dose for 1 month thereafter. All patients were on 300 mg aspirin on the day of the procedure and aspirin treatment was continued without interruption. No oral anticoagulants were used after the procedure. Other antianginal, antihypertensive or lipid-lowering medications were determined on the basis of patients' needs.
Statistical Analysis SPSS for Windows 7.0 software was used for the statistical analysis. Data are expressed as mean value±SD. Differences between the groups were evaluated using the chi-square test or Fisher's exact chi-square test for categorical values. Continuous variables were compared using Student t test. Survival and event-free survival were estimated by Kaplan-Meier curves. A p<0.05 was considered to be statistically significant.
Results
Baseline clinical characteristics of the elderly and younger subjects are given in Table 1 , and baseline angiographic characteristics are presented in Table 2 .
Hypertension, unstable angina pectoris and prior MI were more prevalent in the elderly group (Table 1) in whom 8% of the lesions were Type A, 77% were Type B, and 15% were Type C, according to the AHA/ACC classification. 14 Angiographic findings were available for 67 of the elderly patients after a mean follow-up period of 34±14 months. Thus, assessed overall, long-term clinical followup was available in 78% (93/120), and long-term angiographic follow-up was available in 56% (67/120) of the subjects. Of these 67 patients, 7 had had 2 stents. Consequently stents with angiographic follow-up data made up 54% (74/136) of all stents. There was no difference in the baseline clinical and angiographic characteristics of patients who could or could not be followed clinically. Furthermore, there was no statistically significant difference between the baseline clinical and angiographic features of the elderly cases who did or did not have follow-up angiographic data ( Table 3) .
The in-hospital mortality rate was 0.4% in patients less than 65 years of age and 2.5% in those aged 65 years or more (p=0.055). The difference was close to the statistically significant level.
Outcomes in the Elderly Patients (Table 4)
Angiographic restenosis or total occlusion were observed in 31% (23/74) of the stents for which long-term follow-up angiography was performed.
Of the 7 subjects with 2 stents implanted, 2 had restenosis in both stents and all stents were patent in the remaining 5 subjects. Of the total 21 cases with stent restenosis, PTCA was performed on 3 subjects, CABG was proposed for 10 and the remaining 8 subjects were managed medically. Thus the target lesion revascularization rate was 19.4% (13/67) in the angiographically followed patients. Of the patients with stent restenosis, 62% underwent revascularization with PTCA or CABG.
New lesions had developed in 24% (16/67) of the patients at the long-term follow-up coronary angiography, and of these 16 cases, CABG was proposed for 6, and 8 underwent PTCA/stenting; the remaining 2 subjects had medical treatment only. Consequently the non-target lesion revascularization rate (NTLR) was 21% (14/67) in angiographically followed elderly patients and the total rate of revascularization during follow-up was 40% in angiographically followed patients (27/67) . If the clinically and angiographically followed patients were considered together, the rate of revascularization was 29% (27/93).
Comparison of the new ECG data with the ECG recorded during the stenting procedure revealed a new Qwave MI in 11% (10/93) of the cases.
Of the 93 subjects that we followed clinically, 13 died, which gave a long-term (>3 years) follow-up mortality rate of 14%, reflecting both cardiac and non-cardiac deaths. From the Kaplan-Meier estimates, the cumulative survival rate was, respectively, 93%, 90%, 86% and 82% at 1, 2, 3 and 4 years follow-up after stent implantation, and the cumulative event-free survival was 78%, 69%, 56% and 49%, respectively (Fig 1) . In the younger patients (<65 years of age) the long-term follow-up mortality rate was 9%. Although long-term mortality rate in the elderly patients was higher than in the younger cases, the difference was not statistically significant (p>0.05).
Discussion
PTCA and CABG, currently the common coronary reperfusion methods carried out in the elderly patient population, have been extensively studied and the findings indicate that early phase morbidity and mortality rates after both procedures are higher in elderly subjects than in younger patients. [3] [4] [5] [11] [12] [13] [15] [16] [17] [18] As a consequence, advanced age is considered a risk factor for both interventions and the other factors leading to the high morbidity and mortality seen with CABG and PTCA in elderly patients have also been established: coronary artery disease is the most common, together with a high rate of left main coronary artery involvement, a higher incidence of peripheral artery disease and cerebrovascular disease, more advanced stage of left ventricular dysfunction and the presence of congestive impairment. [3] [4] [5] [11] [12] [13] [15] [16] [17] [18] Stent deployment for the treatment of coronary artery disease has become the most commonly practiced therapeutic percutaneous coronary intervention today, 19, 20 but data on the long-term follow-up results in the elderly population are limited for such a widely practiced procedure. Initially, vascular complications because of the anticoagulant therapy used with coronary stenting were frequent in the general patient population, and even more so in the elderly. 21, 22 With modification of the anticoagulant and antiplatelet therapies, the vascular complications were substantially reduced and stenting has become the main percutaneous coronary intervention procedure in elderly subjects. Early studies examining coronary stenting in elderly subjects suggested that procedural success was high, with good results in the mid-and long-term follow-up; however, the data were conflicting in subsequent studies. In a study comparing the early and 6-month results of intracoronary stent implantation in 3 different age groups (<65 years, 65-75 years and >75 years), MCE did not differ among the age groups either during the in-hospital period or at 6 months. 23 A later study reported that both procedural complications and 6-month results were more unfavorable in patients aged 75 years and over compared with younger subjects. 24 Similarly, Alfonso et al found both in-hospital and long-term results to be more unfavorable in elderly cases, but a difference in the restenosis rates was not found to be associated with age. 25 In our present study, the inhospital mortality rate was higher in the elderly patients.
Restenosis rates vary considerably between studies examining the intermediate and long-term results in elderly subjects: between 22% and 47%. [24] [25] [26] [27] [28] In the 6-month follow-up period in the study of Trabattioni et al, the restenosis rate was 33.3%, 28 whereas for the same length of follow-up it was 47% in the study of De Gregorio et al. 24 Munoz et al, with a mean of 3.0±1.5 years of follow-up, reported a restenosis rate of 22%. 27 Although most of these studies could not find a difference between the elderly and younger groups, De Gregorio et al observed stent restenosis to be higher in elderly subjects. 24 The long-term angiographic restenosis rate in the present elderly subjects was 31%, which when compared with the other reported restenosis rates is lower than that of De Gregorio et al. 24 However, it is close to the restenosis rates detected in other studies with either a follow-up period of 6 months or a follow-up period similar to the present study. [25] [26] [27] [28] In the present subjects, the target lesion revascularization rate as a whole was 14%, and 19.4% in patients with angiographic follow-up, compared with 11.2% and 28%, respectively, in elderly subjects in studies with a follow-up period of 6-12 months. 23, 24, 28 A new coronary lesion developed in 24% of the patients undergoing long-term angiographic follow-up, so the nontarget lesion revascularization was especially high (21%). This is an important finding and indicates that progression of atherosclerosis and development of new coronary lesions are the major problems for elderly patients in the long-term follow-up period.
In elderly patients with coronary stents, death rates vary between 9% and 15% during a 6-12-month follow-up period. 24, 27 As with the in-hospital mortality rate, the longterm mortality rate was higher among the elderly patients (≥65 years) than the younger patients in the present study. The death rate reflects both cardiac and non-cardiac deaths because it was not possible to discriminate cardiac deaths in the follow-up period. In elderly patients, the new Qwave MI rate was 11%.
In the long-term follow-up period the rate of cardiac events such as revascularization, MI and death seems to be high in patients older than 65 years who have coronary stents. This results could be explained by the presence of higher incidences of multi-vessel disease, complex lesions, main stem coronary lesions, unstable angina pectoris and other comorbid factors in the elderly population.
Although restenosis rates in our study do not deviate greatly from the expected long-term figures in younger populations, our results indicate that the potential for major cardiac events is still high among elderly subjects, despite developments in stent technology and medication. The high rate of non-target lesion revascularization in the long term underlines the importance of therapies targeted at the progression of atherosclerosis and prevention of new lesions.
Study Limitations
One of the major limitations was the absence of an angiographically followed control group, so we could not compare the end-points other than death between the elderly and younger patients.
Another major limitation was the low angiographical follow-up rate of the patients. Because of the limited size of the study population who had undergone follow up coronary angiography, this study did not include a multivariable analysis of the factors that are considered to affect the outcome.
